NorthSea Therapeutics has commenced a Phase I clinical trial of SEFA-6179 in adult subjects, intending to obtain a preliminary orphan indication to treat intestinal failure-associated liver disease (IFALD).

The final data from the Phase I trial recruiting healthy volunteers is expected in the third quarter of 2022. It will facilitate the start of an international Phase II trial in individuals with IFALD. The Phase II trial is planned to begin in the first quarter of 2023.

The placebo-controlled, randomised, single and multiple ascending dose Phase I trial will assess the safety, tolerability and pharmacokinetics of SEFA-6179. It plans to enrol nearly 90 healthy subjects in the UK.

An oral, synthetic, medium-chain fatty acid analog (MCFA), SEFA-6179 is intended to preserve the ease of transport to the liver as well as into cells that is characteristic of MCFAs. 

This is also designed to provide improved pharmacological impact by averting quick metabolism.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

In various preclinical models, the molecule directly acts on the liver and was found to impact cholestasis, steatosis, and fibrosis. 

NorthSea Therapeutics CEO Rob de Ree said: “The commencement of this trial is a key milestone in NST’s journey to become a multi-asset company with a robust clinical pipeline of SEFAs. 

“We are excited to develop our first candidate for an orphan indication, especially for one where patients currently have no therapeutic options available.”

In pre-clinical studies, SEFA-6179 was found to have favourable effects in averting parenteral nutrition-induced cholestasis development and liver injury linked to IFALD.

Characterised by hepatic inflammation, cholestasis and steatosis development, IFALD is a multifactorial condition in individuals with intestinal failure and/or substantial resection.